Business Update & Financial Outlook

ID Progressing our broader pipeline Vaccines and Infectious Disease VACCINES V116, our investigational pneumococcal conjugate vaccine specifically designed for adults: - protects against serotypes that are responsible for ~85% of invasive pneumococcal disease in adults ages ≥651 - includes 8 serotypes that are currently not covered by approved vaccines, and are responsible for ~30% of invasive pneumococcal disease in adults ages ≥651 Announced positive topline data for V116 for two Phase 3 trials (STRIDE-3 and STRIDE-6) General Medicine CARDIOMETABOLIC • Completed FDA submission of sotatercept for the treatment of adults with PAH based on the Phase 3 STELLAR trial Presented positive data at EASL from the Phase 2a trial evaluating efinopegdutide, our investigational GLP-1/ glucagon receptor co-agonist, in patients with NAFLD and initiated Phase 2b trial in pre-cirrhotic NASH • Received FDA approval for PREVYMIS for prophylaxis of CMV disease for adult recipients of kidney transplant who are at high-risk of infection COUGH FDA accepted re-submission of the NDA for gefapixant in patients with refractory or unexplained chronic cough 1. Centers for Disease Control and Prevention, IPD serotype data 2019, as compiled from data provided through Active Bacterial Coresurveillance (ABCs). MERCK 23

View entire presentation